#India #Mumbai #ophthalmology #Lupin Limited #VISUfarma

Lupin Completes Strategic Acquisition of VISUfarma

Lupin Limited, a prominent player in the global pharmaceutical industry, has officially announced the completion of its acquisition of VISUfarma B.V., a leading European company specializing in ophthalmology. This acquisition marks a pivotal development in Lupin's strategy to broaden its specialty care offerings and bolster its presence in key European markets.

Founded through a merger in 2016, VISUfarma has carved a niche for itself in providing essential eye care solutions with a robust portfolio encompassing over 60 branded products. Their offerings target a range of conditions including dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. The market reach of VISUfarma spans crucial European territories, including Italy, the UK, Spain, Germany, and France, backed by a knowledgeable team with in-depth expertise in ophthalmology.

The acquisition is seen as a strategic fit for Lupin, which will now significantly enhance its capabilities to meet the rising global demand for innovative eye care solutions. This demand is notably driven by factors such as an aging population and the increasing incidence of diabetes-related eye complications, which necessitate advanced treatment options.

Vinita Gupta, Lupin's CEO, expressed her enthusiasm for the acquisition, stating, "The VISUfarma acquisition is an exciting milestone for Lupin, having added a differentiated portfolio of more than 60 innovative eye health products. This move is not only immediately accretive but also positions us strategically to expand across Europe and accelerate the growth of our specialty franchise."

In alignment with this strategic acquisition, Paolo Cioccetti, CEO of VISUfarma in Italy, shared his optimism about the collaboration. He emphasized that Lupin's global expertise and visionary approach would provide the necessary support to elevate VISUfarma’s offerings, ensuring that they can collectively make a meaningful impact in the advancement of eye care throughout Europe and beyond.

As a company, Lupin Limited is headquartered in Mumbai, India, and boasts a comprehensive presence across more than 100 markets worldwide. Renowned for a variety of pharmaceutical products—including both branded and generic formulations—Lupin also invests in complex generics and biotechnology products. Their established foothold is particularly strong in the U.S. and India, across many therapeutic areas such as respiratory health, cardiovascular issues, diabetes, infectious diseases, and women's health.

Lupin's strategic approach is underpinned by a commitment to enhance patient health outcomes through continuous innovation. With 15 cutting-edge manufacturing facilities and seven global research centers, they employ over 24,000 professionals dedicated to driving advancements in healthcare.

In addition to the acquisition benefits, the collaboration with VISUfarma will integrate their commercial infrastructure with Lupin's extensive capabilities. The transaction promises to accelerate the reach of eye care products and expand market access, thereby advancing the company’s mission to improve patient health outcomes through innovative solutions.

To learn more about Lupin and its latest initiatives, visit Lupin's official website or check out their company updates on LinkedIn. The emphasis on improving health standards remains a central focus as Lupin progresses in its integration of VISUfarma, with an eye toward addressing the healthcare demands of the future.